Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Motif Bio PLC invited to prestigious life sciences partnering conference

BIO-Europe Spring is designed to provide top level partnering opportunities for smaller life science companies
Motif Bio PLC invited to prestigious life sciences partnering conference
The conference annually attracts an international "who's who" from biotech, pharma, and finance for three days networking and meetings

Motif Bio plc (LON:MTFB) is  to present at the prestigious BIO-Europe Spring conference in Stockholm next month to help its search for a partner for its new antibiotic iclaprim.

Graham Lumsden, Motif Bio’s chief executive, will give the presentation on Tuesday, 5 April.

BIO-Europe Spring  is designed to provide top level partnering opportunities for smaller life science companies.

The conference annually attracts an international "who's who" from biotech, pharma, and finance for three days networking and meetings, Motif said.

The group recently dosed its first patient in one of two phase III clinical trials planned for iclaprim while it also appointed The Fulford Group to assist with the commercialisation of the drug.

Lumsden recently told Proactive Investors the company is looking for “one or two partners during 2016” to help commercialise iclaprim globally, and that the Fulford Group, which “specialises in finding partners for companies like Motif,” will aid the firm to do this.

PhilW.jpg
Why Invest In Motif Bio Plc? Read More Here

Register here to be notified of future MTFB Company articles
View full MTFB profile

Motif Bio Plc Timeline

Big Picture
January 19 2017
Article
November 24 2016

Related Articles

picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use